Anti-CTLA-4(tuvonralimab biosimilar) mAb Cat. No. BME100712



PRODUCT INFORMATION

Common Name	PSB105;PSB-105;PSB-205 (cocktail with Tuvonralimab);PSB205 (cocktail with Tuvonralimab);QL1706 (cocktail with Tuvonralimab)
Conjugate	Unconjugated
Synonyms	CD;GSE;GRD4;ALPS5;CD152;CTLA-4;IDDM12;CELIAC3
Applications	N/A
Recommended Dilutions	N/A
Formulation & Reconstitution	Lyophilized from sterile PBS, pH 7.4. Normally 5 % – 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Host Species	N/A
lgG type	lgG1
Reactivity	Human
Target	CTLA-4
Uniprot ID	P16410
Description	Anti-CTLA-4(tuvonralimab biosimilar[]lgG1) mAb
Delivery	3-4 weeks
Storage & Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature. Research grade biosimilar. Not for use in therapeutic
Background	or diagnostic procedures for humans or animals.
Usage	Research use only
DIMA Disclaimer	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.

